EGFR Antikörper (pTyr845)

Produktnummer ABIN967602

Produktdetails anti-EGFR Antikörper

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Bindungsspezifität: pTyr845

Reaktivität: Human, Maus, Ratte

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EGFR Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Marke: BD Pharmingen™

Kreuzreaktivität: Maus, Ratte (Rattus)

Produktmerkmale: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
3. Please refer to us for technical protocols.

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Phosphorylated Human EGF Receptor Peptide

Klon: 12A3

Isotyp: IgG1 kappa

Anwendungsinformationen

Kommentare:

Related Products: ABIN967389

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4°C.

Referenzen für anti-EGFR Antikörper (ABIN967602)

Hristozova, Konschak, Budach, Tinhofer: "A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers." in: Cytometry. Part A : the journal of the International Society for Analytical Cytology, Vol. 81, Issue 6, pp. 489-95, (2012) (PubMed).

Boerner, Demory, Silva, Parsons: "Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II." in: Molecular and cellular biology, Vol. 24, Issue 16, pp. 7059-71, (2004) (PubMed).

Mendelsohn, Baselga: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 14, pp. 2787-99, (2003) (PubMed).

Moro, Dolce, Cabodi, Bergatto, Boeri Erba, Smeriglio, Turco, Retta, Giuffrida, Venturino, Godovac-Zimmermann, Conti, Schaefer, Beguinot, Tacchetti, Gaggini, Silengo, Tarone, Defilippi: "Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines." in: The Journal of biological chemistry, Vol. 277, Issue 11, pp. 9405-14, (2002) (PubMed).

Wu, Graves, Gill, Parsons, Samet: "Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation." in: The Journal of biological chemistry, Vol. 277, Issue 27, pp. 24252-7, (2002) (PubMed).

Olayioye, Neve, Lane, Hynes: "The ErbB signaling network: receptor heterodimerization in development and cancer." in: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, (2000) (PubMed).

Biscardi, Maa, Tice, Cox, Leu, Parsons: "c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function." in: The Journal of biological chemistry, Vol. 274, Issue 12, pp. 8335-43, (1999) (PubMed).

Details zu EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Andere Bezeichnung: EGF Receptor (EGFR Produkte)

Synonyme: C-erb antikoerper, CG10079 antikoerper, D-EGFR antikoerper, D-Egf antikoerper, DEGFR antikoerper, DER antikoerper, DER flb antikoerper, DER/EGFR antikoerper, DER/faint little ball antikoerper, DER/top antikoerper, DER/torpedo antikoerper, DER1 antikoerper, DEgfr antikoerper, Degfr antikoerper, Der antikoerper, DmHD-33 antikoerper, Dmel\\CG10079 antikoerper, EFG-R antikoerper, EGF-R antikoerper, EGFR antikoerper, EGFr antikoerper, EGfr antikoerper, EK2-6 antikoerper, Egf antikoerper, Egf-r antikoerper, EgfR antikoerper, El antikoerper, Elp antikoerper, Elp-1 antikoerper, Elp-B1 antikoerper, Elp-B1RB1 antikoerper, HD-33 antikoerper, TOP antikoerper, Torpedo/DER antikoerper, Torpedo/Egfr antikoerper, c-erbB antikoerper, d-egf-r antikoerper, dEGFR antikoerper, dEGFR1 antikoerper, dEgfr antikoerper, der antikoerper, egfr antikoerper, flb antikoerper, l(2)05351 antikoerper, l(2)09261 antikoerper, l(2)57DEFa antikoerper, l(2)57EFa antikoerper, l(2)57Ea antikoerper, mor1 antikoerper, top antikoerper, top/DER antikoerper, top/flb antikoerper, torpedo/Egfr antikoerper, torpedo/egfr antikoerper, EGFR12 antikoerper, EGFR15 antikoerper, egfr1 antikoerper, Erbb2 antikoerper, ERBB antikoerper, ERBB1 antikoerper, HER1 antikoerper, PIG61 antikoerper, mENA antikoerper, ErbB-1 antikoerper, Errp antikoerper, 9030024J15Rik antikoerper, AI552599 antikoerper, Erbb antikoerper, Errb1 antikoerper, Wa5 antikoerper, wa-2 antikoerper, wa2 antikoerper, epidermal growth factor receptor antikoerper, Epidermal growth factor receptor antikoerper, epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) antikoerper, EGFR antikoerper, Egfr antikoerper, egfra antikoerper, egfr1 antikoerper, LOC5564544 antikoerper

Hintergrund: Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. In addition, c-Src-dependent phosphorylations at other sites, such as tyrosine 845 (Y845) in the kinase domain, regulate the receptor's kinase activity. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies.
The 12A3 monoclonal antibody recognizes the phosphorylated Y845 in the protein tyrosine kinase domain of human EGFR.

Molekulargewicht: 175 kDa

Pathways: NF-kappaB Signalweg, RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteine